On August 25th, 2018, Resverlogix supported a satellite symposium at the European Society of Cardiology (ESC) Congress in Munich, Germany: "LDL-c: Done Deal, Next Epigenetics?"
Introduction - Ulrich Laufs, MD – Leipzig, Germany.
Erik Stroes, MD – Amsterdam, Netherlands. "The real residual risk in patients with CVD & diabetes: The promise of epigenetics."
Jorge Plutzky, MD – Boston, USA. "Understanding epigenetics: The potential rationale for BET inhibition in management of CVD."
Kausik Ray, MD - London, UK. "A clinical view on BET inhibition in targeting residual risk in CVD and diabetes."
Discussion & Summary. Co-Chairmen: Kausik Ray, MD and Ulrich Laufs, MD.
Video Presentations & Symposium Highlights can be accessed HERE